Items where authors include "Cuzick, J."

Article

French, D.P. orcid.org/0000-0002-7663-7804, McWilliams, L. orcid.org/0000-0002-6414-2732, Payne, K. orcid.org/0000-0002-3938-4350 et al. (28 more authors) (2025) The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme. Programme Grants for Applied Research, 13 (13). ISSN 2050-4322

Gill, S., Chen, R., Lamb, B.W. orcid.org/0000-0003-2220-893X et al. (5 more authors) (2025) Interventions for patients with prostate cancer on active surveillance: a narrative review. BJU International. ISSN 1464-4096

Brentnall, A., Atakpa, E., Hill, H. orcid.org/0000-0002-0908-5595 et al. (5 more authors) (2023) An optimization framework to guide choice of thresholds for risk-based cancer screening. npj Digital Medicine, 6. 223. ISSN 2398-6352

Sestak, I., Blake, G., Patel, R. et al. (4 more authors) (2021) Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years : 7-year results from the IBIS-II prevention trial. British Journal of Cancer, 124 (8). pp. 1373-1378. ISSN 0007-0920

Sestak, I., Blake, G.M., Patel, R. et al. (3 more authors) (2019) Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 124. pp. 83-88. ISSN 8756-3282

Forbes, J.F., Sestak, I., Howell, A. et al. (13 more authors) (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet, 387 (10021). pp. 866-873. ISSN 0140-6736